REGN — Regeneron Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $81.99bn
- $76.70bn
- $14.34bn
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement
US RESEARCH ROUNDUP-Arxis, Cigna, Vylor
Brief: Regeneron Phase 2 Trial Shows Trevogrumab Prevents Muscle Loss During GLP-1 Weight Loss
Brief: Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients
Sanofi’s Regeneron fix requires extra shot of M&A
Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute (updated)
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial (updated)
Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial
Ocular Therapeutix tumbles on rival Kodiak's trial win, analyst calls selloff overdone
Kodiak Sciences rises after eye-disease drugs meet late-stage trial goals
Kodiak Sciences rises after eye-disease drugs meet trial goals
US FDA approves Mirum's drug for rare bone disorder (updated)
US FDA approves Mirum's drug for rare bone disorder
Live Markets: RBC says AI weakness appears to be fueling biotech rally
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements